Moventra Medical
High-demand primary implants featuring advanced biocompatibility, HA coatings, and sterile-packed configurations designed for immediate clinical deployment in Australian hospitals.
Australia boasts one of the most rigorous and transparent clinical environments for joint arthroplasty globally. According to the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), over 65,000 hip and knee replacements are performed annually. The market demands implants with proven survivorship, extremely low cumulative revision rates, and precise fitment across diverse patient demographics.
Driven by an aging population, rising rates of osteoarthritis, and active lifestyles among seniors, Australian public and private hospitals (e.g., Ramsay Health Care, Healthscope) require reliable, uninterrupted supply lines of primary and revision joint prosthesis. Moventra Medical Technology aligns its design principles with the strict expectations of the Therapeutic Goods Administration (TGA) and the requirements of private health insurance Prostheses List reforms, which emphasize high clinical efficacy coupled with cost containment.
Design parameters aligned with clinical metrics reported in the Australian national registry to minimize aseptic loosening and revision rates.
Assisting Australian distributors in navigating the shifting reimbursement models with competitive, high-value OEM manufacturing cost structures.
Providing streamlined single-use or high-durability instrument trays that match the workflow efficiency in Australian operating theaters.
Deploying cutting-edge engineering solutions across veterinary medicine, private cosmetic surgeries, public health systems, and localized research trials in Oceania.
Supplying state-level health departments (e.g., NSW Health, Queensland Health) with bulk, standardized knee and hip systems. Moventra supports procurement tenders with detailed material traceability and long-term manufacturing capacity guarantees.
Supporting Australia's growing trend toward outpatient joint replacements. Our low-profile, ergonomically designed instrument kits permit rapid sterilization cycles and compact storage, lowering operating costs in boutique day hospitals.
Catering to the premium veterinary care segment in Melbourne, Sydney, and Brisbane. Moventra provides dedicated canine total hip systems and micro-arthroplasty systems to specialize in veterinary specialist centers and university teaching hospitals.
In a post-pandemic landscape plagued by shipping delays and component shortages, Moventra stands out by offering integrated supply chain stability. Located in China's advanced manufacturing corridor, our 18,600 m² facility is fully self-sustained. We control every stage of production: from raw material inspection (sourcing biocompatible Titanium Alloy Ti6Al4V ELI, CoCrMo, and UHMWPE) to precise multi-axis CNC machining, ultrasonic cleaning, and cleanroom sterile packaging.
For the Australian market, this translates to predictable lead times, bypass of localized distributor bottlenecks, and direct access to production queues. With over 1,120 supply chain partners, we buffer macro-economic disruptions, maintaining constant stock reserves of standard sizes to satisfy urgent hospital requirements.
| Supply Chain Attribute | Moventra Standard | Australian Advantage |
|---|---|---|
| Production Lead Time | 4-6 Weeks for Custom Batches | Minimizes inventory holding costs |
| Raw Materials | ISO 5832-3 Titanium, ASTM F75 CoCrMo | Full traceability certification |
| Sterility Level | Class 10,000 Cleanroom (ISO 7) | Ready-to-use direct surgical delivery |
| QC Protocols | 100% Dimensional & Visual Testing | Guarantees zero-defect arrival |
Established in 2017, Moventra integrates research, development, and advanced manufacturing to deliver next-generation orthopedic systems worldwide.
| Item | Details |
|---|---|
| Company Name | Moventra Medical Technology (China) Co., Ltd. |
| Brand | Moventra |
| Established | 2017 |
| Facility Area | 18,600 m² |
| Annual Export Revenue | USD 23.8 Million |
| Export Experience | 7 Years |
| Industry Experience | 13 Years |
| Quality Inspection | 100% Quality Inspection Before Shipment |
| Product Inspection Methods | Dimensional Inspection, Material Analysis, Surface Finish Inspection, Mechanical Performance Testing, Sterility Verification |
| Quality Control Staff | 48 Specialists |
| Business Type | Manufacturer, OEM & ODM, Exporter |
| Main Markets | North America, Europe, South America, Middle East, Southeast Asia, Australia |
| Supply Chain Partners | 1,120 Partners |
| Main Customer Types | Medical Device Brands, Orthopedic Distributors, Hospitals, Importers, Government Procurement Projects |
| R&D Capability | Independent Product Design, Rapid Prototyping, OEM/ODM Development, Customized Engineering Solutions |
| Customization Options | Logo Customization, Packaging Customization, Product Design Customization, Drawing-Based Manufacturing, Sample-Based Manufacturing |
| New Products Released Last Year | 156 Items |
| R&D Engineers | 86 Engineers |
Ensuring future clinical relevance through research in advanced materials, biomimetic coatings, and 3D printing capabilities.
Developing 3D-printed trabecular structures to encourage bone ingrowth. Direct titanium laser sintering (DMLS) creates scaffolds resembling human cancellous bone.
Improving Vitamin E-stabilized Highly Cross-linked Polyethylene (XLPE) liners to decrease wear and extend implant life for younger, active patients.
Investigating embedded micro-sensor technologies to provide post-operative feedback on joint kinematics, load patterns, and early signs of infection.
We provide comprehensive support for medical registration processes in Australia. Our regulatory team prepares detailed documentation (including design dossiers, bio-compatibility reports, clinical evaluation data, and sterilization validation reports) to support localized TGA registration and inclusion on the Australian Register of Therapeutic Goods (ARTG).
To reduce freight times to main hubs like Sydney, Melbourne, and Fremantle, we maintain strong partnerships with major logistics providers. Our custom-clearance documentation is formatted to comply with Australian Border Force guidelines, preventing delivery delays for critical orthopedic components.
Providing ISO 13485:2016 audit reports and CE certs to streamline your TGA application processes.
Double-barrier sterile tyvek packaging compliant with ISO 11607, ensuring a 5-year shelf-life stability.
Browse our selection of orthopedic implants, specialized joint revision instruments, veterinary implants, and orthopedic meshes.
Addressing key queries related to regulatory alignment, material specifications, MOQ, and international shipping to Australia.
Yes, we provide technical documentation support for TGA (Therapeutic Goods Administration) applications. This includes ISO 13485:2016 certificates, CE Class III design dossiers, biocompatibility reports (ISO 10993 series), and cleanroom sterility validation records.
We use medical-grade, traceable materials sourced from certified suppliers: Titanium Alloy (Ti6Al4V ELI) conforming to ASTM F136/ISO 5832-3; Cobalt-Chromium-Molybdenum (CoCrMo) conforming to ASTM F75/ISO 5832-4 for joint bearing surfaces; and medical-grade Ultra-High-Molecular-Weight Polyethylene (UHMWPE) for articulating inserts.
Our quality department is staffed by 48 quality specialists who employ coordinate measuring machines (CMM), surface roughness testers, and metallographic microscopes. We enforce a 100% pre-shipment dimensional inspection policy to maintain strict dimensional compliance across all manufacturing runs.
Our standard production lead time for customized implant sizes or surgical instrumentation batches is 4 to 6 weeks. Minimum Order Quantities (MOQs) depend on the item type and design complexity. Standard implant designs have highly flexible MOQs to support distributor trials.
We offer both options. Our standard configurations are washed in purified water systems, assembled, double-sterile packed in Class 10,000 (ISO Class 7) cleanrooms, and Gamma irradiated (producing a Sterility Assurance Level of 10⁻⁶). Non-sterile options are also available for localized hospital autoclave processing.
We supply dedicated veterinary hip and knee replacement lines (such as Bipolar systems and specialized tooling). These are engineered for specific canine anatomy, offering veterinary orthopedic surgeons precise implant scaling to improve postoperative outcomes.